HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Tirzepatide cut major kidney events 23% vs dulaglutide in SURPASS-CVOT post-hoc analysis

Louis Nervegna · May 13, 2026 · ♥ 1 reactions · 2 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Kidney healthInsulin resistance & diabetes
AI summary & key facts

Louis shares a summary of a post-hoc kidney analysis of SURPASS-CVOT in people with type 2 diabetes and heart disease. Tirzepatide gave greater kidney protection than dulaglutide, supporting the kidney-protective role of GLP-1-based therapies.

More evidence that GLP1’s protect the kidneys in diabetics.

#glp1HD #kidneysHD #diabetesHD

Research cited

GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of kidney disease.

This new post-hoc analysis of SURPASS-CVOT’s kidney outcomes shows greater kidney protection with tirzepatide (#mounjaro) versus dulaglutide (Trulicity) in people with type 2 diabetes and heart disease.

PMID: 42114520

No photo description available.
← newer: Fadogia agrestis testosterone supplement untested in humans;older: GLP-1 use tied to 91% lower all-cause death in women with br →